Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vociprotafib - REVOLUTION Medicine

Next Previous
Search
Drug Profile

Vociprotafib - REVOLUTION Medicine

Alternative Names: RMC-4630; SAR 442720

Latest Information Update: 21 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REVOLUTION Medicines
  • Developer Amgen; Netherlands Cancer Institute; REVOLUTION Medicines; Sanofi; The Lustgarten Foundation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein tyrosine phosphatase non-receptor type 11 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Solid tumours
  • Phase I Pancreatic cancer

Most Recent Events

  • 08 Sep 2024 Pharmacokinetics data from a clinical trial in Solid tumours presented at the 2024 American College of Clinical Pharmacology Annual Meeting (ACCP-2024)
  • 08 Sep 2024 Revolution Medicines in collaboration with Sanofi initiates a clinical trial for Solid tumours (Combination therapy, Late-stage disease) (PO), before September 2024
  • 04 Apr 2024 Revolution Medicines, Sanofi and Mirati Therapeutics terminates a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease) in USA, Argentina, Australia, Chile, South Korea, Netherlands, Spain, and Taiwan (PO) (NCT04418661) (EudraCT2020-000436-22)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top